secwatch / observer

8-K filed June 2, 2026, 7:05 AM ET ticker VERA CIK 0001831828

regulatory confidence high sentiment positive materiality 0.75

Vera Therapeutics announces FDA alignment on earlier eGFR analysis for atacicept; results expected Q3 2026

Vera Therapeutics, Inc.

FDA agreed to revised ORIGIN 3 eGFR analysis plan to support potential full approval of atacicept in IgA Nephropathy.
eGFR results now expected in the third quarter of 2026.
Company plans to submit supplemental Biologics License Application for full approval in Q4 2026.
Alignment could accelerate path to full approval for atacicept.

Featured in Daily 8-K Digest

Selected #7 for 2026-06-02. Read digest

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-252475
form_type: 8-K
ticker: VERA
cik: 0001831828
company_name: Vera Therapeutics, Inc.
filed_at: 2026-06-02T11:05:16+00:00
discovered_at: 2026-06-02T11:10:00.234617+00:00
generated_at: 2026-06-02T11:11:26.547953+00:00
sec_items: ["8.01"]
event_type: regulatory
sentiment: positive
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-252475
json_url: https://secwatch.observer/filing/0001193125-26-252475.json
markdown_url: https://secwatch.observer/filing/0001193125-26-252475.md
text_url: https://secwatch.observer/filing/0001193125-26-252475.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1831828/000119312526252475/0001193125-26-252475-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1831828/000119312526252475/vera-20260602.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

CING

Cingulate receives FDA Complete Response Letter for CTx-1301; no safety/efficacy issues, CMC-only

Cingulate Inc. June 2, 2026, 8:10 AM ET regulatory Items 7.01, 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

MNKD

FDA approves Afrezza for pediatric diabetes patients ages 6+

MANNKIND CORP June 2, 2026, 8:00 AM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

TXNM

TXNM subsidiaries: TNMP rate settlement with $20.5M storm rider, PNM resource plan with 1.65 GW renewables

TXNM ENERGY INC June 1, 2026, 5:54 PM ET regulatory Items 7.01, 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

LESL

Leslie's regains Nasdaq compliance for minimum market value of publicly held shares

Leslie's, Inc. June 1, 2026, 4:28 PM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

OTLK

Outlook Therapeutics resubmits BLA for ONS-5010 to FDA; Class 1 review, PDUFA in 60 days

Outlook Therapeutics, Inc. June 1, 2026, 9:15 AM ET regulatory Items 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

VYGR

FDA clears IND for VY1706, Voyager's tau-silencing gene therapy for Alzheimer's

Voyager Therapeutics, Inc. June 1, 2026, 8:00 AM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

EXFY

Expensify regains Nasdaq minimum bid price compliance

Expensify, Inc. May 29, 2026, 5:15 PM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

SLXN

Silexion Therapeutics completes 1-for-10 reverse share split; warrants adjusted

Silexion Therapeutics Corp May 29, 2026, 7:00 AM ET regulatory Items 3.03, 5.03, 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-26-252475

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.